Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancerDamien Destouches(Université Paris-Est Créteil), Francis Vacherot(Inserm)OncotargetMarch 14, 201610.18632/oncotarget.8043Cited by 18SaveCiteExport RISWatch citationsRelated PapersIncreased expression of class III β-tubulin in castration-resistant human prostate cancer|British Journal of Cancer|2009|84CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities|Oncotarget|2015|27